Langer–Saldino Achondrogenesis (Achondrogenesis Type II)

Langer–Saldino achondrogenesis is a very rare and very severe bone growth disorder in babies. Doctors also call it achondrogenesis type II. It happens because the body cannot make type II collagen in a normal way. Type II collagen is a key building block for cartilage. Cartilage is the soft “model” that later turns into bone by a process called endochondral ossification. When collagen is faulty, the growth plates in the long bones do not work well. As a result, the baby develops very short arms and legs, a small, narrow chest, and poorly formed ribs and spine. The lungs cannot grow enough inside the small chest, so severe breathing problems occur right at birth. Sadly, the condition is usually lethal before or shortly after birth.

Langer–Saldino achondrogenesis—also called achondrogenesis type II (ACG2)—is a very rare, very severe genetic disorder that affects how a baby’s cartilage turns into bone before birth. Cartilage is the “soft model” that bones grow from. In this condition, the body cannot build type II collagen properly. Type II collagen is a major building block in the growing skeleton (spine, ribs, long bones) and in parts of the eye and ear. Because the collagen is faulty, the fetus develops extremely short arms and legs (micromelia), a very small, narrow chest, and underdeveloped lungs. Bones in the spine and pelvis do not mineralize well, and the long bones are very short. The face may look flat, and some babies have a small lower jaw or a cleft palate (Pierre Robin sequence). The disorder is usually lethal before birth or shortly after birth, mainly because the lungs are too small to support breathing. Most cases are caused by a new (“de novo”) change in a gene called COL2A1 and are autosomal dominant, which means one changed copy is enough to cause the disease; however, the change almost always arises for the first time in that pregnancy. NCBI+1MedlinePlus

The disorder is caused by a harmful change (pathogenic variant) in the COL2A1 gene. This gene tells the body how to make type II collagen. Most cases are new (de novo) mutations that happen by chance in the egg or sperm. Parents usually do not carry the variant.

This condition is part of the “type II collagenopathy” family. That family includes other skeletal disorders such as spondyloepiphyseal dysplasia congenita and Stickler syndrome, but Langer–Saldino achondrogenesis is the most severe end of that spectrum.

---

Other names

• Achondrogenesis type II

• Langer–Saldino achondrogenesis

• ACG2 (a short code often used in genetics)

• Type II collagenopathy, perinatal-lethal form

• Achondrogenesis, Langer–Saldino type

(All of these refer to the same condition.)

---

Types

“Achondrogenesis” is a group name. Doctors divide it into subtypes based on genes, X-rays, and pathology:

1. Achondrogenesis type IA (Houston–Harris):
   Usually autosomal recessive. Very poor bone mineralization, especially in skull and spine. Caused by changes in TRIP11 (also known as GMAP-210).

2. Achondrogenesis type IB (Fraccaro):
   Usually autosomal recessive. Severe skeletal under-ossification with distinctive hand/foot findings. Caused by SLC26A2 variants (a sulfate transporter also involved in diastrophic dysplasia).

3. Achondrogenesis type II (Langer–Saldino):
   Autosomal dominant, almost always de novo. Caused by COL2A1 variants that disrupt type II collagen. Skull ossification is better than in type I, but the spine, ribs, pelvis, and long bones are severely affected.

(Your topic here is type II—the Langer–Saldino form.)

---

Causes

Note: In this disease, “cause” mainly means genetic and cellular mechanisms that lead to the final problem. Lifestyle or pregnancy behavior does not cause it.

1. Pathogenic variant in COL2A1: The main cause. The gene for type II collagen is changed, so the protein is abnormal.

2. Dominant-negative effect: A single bad collagen chain can poison the whole collagen triple helix. This makes most collagen fibers weak or unusable.

3. Glycine substitutions in the helix: Replacing tiny glycine with a bigger amino acid bends or blocks the collagen helix, stopping proper folding.

4. Splice-site variants: The gene message is mis-read, creating skipped exons or extra fragments. The collagen chain becomes faulty.

5. Nonsense/frameshift variants: Early stop signals or shifted reading frames make the chain incomplete. The body cannot build normal fibers.

6. Endoplasmic reticulum stress (UPR): Misfolded collagen builds up inside cartilage cells. The cell becomes stressed and may die.

7. Abnormal secretion of collagen: Even if made, the collagen may not leave the cell correctly, so the matrix outside the cell stays weak.

8. Defective cartilage matrix assembly: Collagen II fails to bind and align with proteoglycans and other collagens. The growth plate framework collapses.

9. Disorganized growth plate columns: Chondrocytes cannot line up into neat columns. Endochondral ossification stalls.

10. Reduced hypertrophic zone: The late stage of cartilage that should turn into bone is too thin or absent. Bones stay short.

11. Defective mineralization signals: With a broken matrix, signals for calcium deposition are weak, so bone hardening is poor.

12. Pelvic and rib malformation cascade: Weak cartilage templates create shallow pelvis and short ribs, which later limit lung growth.

13. Spinal body under-ossification: Vertebral bodies form poorly, causing a soft, unstable spine on X-ray.

14. Thoracic narrowing: Malformed ribs and small chest cavity restrict lung space inside the womb.

15. Pulmonary hypoplasia: Because the chest is small, lungs do not grow to normal size. This is the major cause of early death.

16. De novo mutation risk with paternal age: New mutations tend to rise with higher paternal age, slightly increasing risk.

17. Germline mosaicism (rare): A parent may carry the variant in some egg or sperm cells but not in their body cells, so it is hidden but can recur.

18. Post-zygotic mosaicism (rare): The variant can arise early after conception, affecting many tissues, including cartilage.

19. Type II collagen network fragility: Even if some collagen is made, the overall fiber network is fragile and tears under normal growth forces.

20. Not caused by environment or infection: Routine medicines, diet, exercise, or common infections do not cause this genetic disorder.

---

Symptoms and clinical features

1. Very short arms and legs (severe micromelia): Limbs are much shorter than normal for age.

2. Short trunk and neck: The torso looks compact because the spine and ribs are under-ossified.

3. Small, narrow chest: The rib cage is tiny and bell-shaped. This limits breathing ability.

4. Breathing failure at birth: Because lungs are small, the baby often cannot breathe well, even with help.

5. Large head for body size: The skull is relatively better ossified, so the head can look proportionally large.

6. Flat midface and depressed nasal bridge: Facial bones lack normal projection.

7. Cleft palate (sometimes): The roof of the mouth may be split, causing feeding and airway problems.

8. Abdominal protuberance: The tummy may look large compared to the chest.

9. Short, broad hands and feet: The digits appear short and stubby on exam and X-ray.

10. Hip, knee, and elbow contractures: Limited joint movement is common due to abnormal joints and soft tissues.

11. Soft, unstable spine: Poor vertebral ossification makes the spine structurally weak.

12. Polyhydramnios on prenatal scans: Extra amniotic fluid may be seen during pregnancy.

13. Fetal hydrops or edema (in some cases): Fluid can build up in fetal tissues because of severe disease.

14. Poor muscle tone after birth: Hypotonia may be present due to general illness and skeletal restriction.

15. Perinatal death or very short survival: Most babies pass away before birth or soon after, mainly from lung underdevelopment.

---

Diagnostic tests

Physical Exam

1. Newborn dysmorphology exam:
   A doctor carefully looks at body shape, limb length, chest size, and facial features. This first look often points strongly toward a lethal skeletal dysplasia.

2. Anthropometric measurements (length, head, chest, arm/leg segments):
   Exact numbers show how short the limbs are and how small the chest is compared with the head. These data guide the diagnosis and help compare with known patterns.

3. Respiratory assessment and Apgar scoring:
   The team checks breathing effort, color, and heart rate in the first minutes. Severe distress supports the suspicion of a lethal, chest-restrictive disorder.

4. Clinical genetics evaluation and family history:
   A genetics specialist reviews pregnancy history, previous births, and any family patterns. This helps with counseling and next steps in testing.

Manual Tests

5. Joint range-of-motion exam:
   The doctor gently moves joints to see if they are stiff or unstable. Limited motion and contractures are common in severe skeletal dysplasia.

6. Hip stability testing (Ortolani/Barlow maneuvers):
   These gentle tests check if the hips are dislocated or unstable, which often happens when the pelvis and femoral heads are malformed.

7. Palate and airway check (oral exam and suck reflex):
   The clinician looks for a cleft palate and tests early feeding reflexes, because facial and palate changes can complicate feeding and breathing.

Laboratory and Pathological Tests

8. Chorionic villus sampling (CVS) with genetic testing (prenatal):
   A small sample from the placenta in the first trimester can be used to test COL2A1 if ultrasound suggests a severe skeletal disorder.

9. Amniocentesis with genetic testing (prenatal):
   A sample of amniotic fluid taken in the second trimester allows DNA testing for COL2A1 when short limbs and a small chest are seen.

10. Targeted COL2A1 sequencing (postnatal or prenatal):
    DNA sequencing looks directly for disease-causing variants. This is the key confirmatory test for Langer–Saldino achondrogenesis.

11. Deletion/duplication analysis (e.g., MLPA or NGS-based CNV):
    If sequencing is negative, this looks for larger missing or extra pieces of the gene that standard sequencing can miss.

12. Fetal or neonatal exome/genome sequencing:
    If the type is unclear, broader sequencing can detect changes in COL2A1 or other genes from the achondrogenesis spectrum (TRIP11, SLC26A2).

13. Growth plate histology (postmortem, if consented):
    Microscopy of cartilage shows disorganized chondrocyte columns and abnormal matrix typical of a type II collagenopathy. This supports the genetic result.

Electrodiagnostic Tests

14. Fetal cardiotocography (non-stress test) in late pregnancy:
    Monitors fetal heart rate and movement. While not specific for bone disease, it tracks fetal well-being when severe anomalies are present.

15. Neonatal pulse oximetry and capnography (during support):
    Measures oxygen levels and ventilation. These tests document the severe breathing compromise caused by the tiny chest and small lungs.

Imaging Tests

16. Prenatal ultrasound with long-bone measurements:
    A key screening test. Femur and humerus length far below normal, plus a narrow, bell-shaped chest and short ribs, strongly suggest achondrogenesis.

17. 3D/4D ultrasound (prenatal):
    Provides clearer views of facial profile, ribs, pelvis, and hands/feet. Helps distinguish type II from other lethal skeletal dysplasias.

18. Fetal MRI (usually second/third trimester):
    Measures lung size and structure and confirms chest narrowing. Supports delivery planning and counseling.

19. Postnatal skeletal survey (full X-ray series):
    Shows very short long bones, poor ossification of vertebral bodies and pelvis, and short ribs. Skull ossification is relatively better in type II.

20. Low-dose CT with 3D reconstruction (postnatal or postmortem):
    Maps bone geometry in detail, helping confirm pattern and supporting the genetic diagnosis when radiographs are hard to interpret.

Non-pharmacological supports

Important note: because ACG2 is uniformly lethal, the goal of any “therapy” is comfort for the baby and support for the family, not cure. Below, “physiotherapy” items describe gentle comfort measures rather than rehabilitation.

A) Physiotherapy-style comfort measures

1. Comfort positioning and nesting
   Description: Use soft rolls and swaddles to support the baby in a flexed, midline posture, reducing strain on short, fragile limbs and the small chest.
   Purpose: Ease breathing effort, reduce agitation, and prevent pressure spots.
   Mechanism: Stable joint angles reduce muscle tension and pain; midline positioning optimizes diaphragmatic mechanics in a small thorax.
   Benefits: Calmer baby, lower energy use, improved bonding during cuddles; helps nurses and parents offer skin-to-skin time more safely.

2. Skin-to-skin (kangaroo) when feasible
   Description: With monitoring and guidance, place the baby against a caregiver’s chest for warmth and contact.
   Purpose: Provide comfort, stabilize temperature, and support bonding in the brief time available.
   Mechanism: Skin contact triggers calming hormones (oxytocin) and improves thermal regulation without extra metabolic stress.
   Benefits: Better comfort scores, meaningful family moments, reduced crying.

3. Gentle containment holds
   Description: Cup hands around shoulders/hips without moving limbs; avoid traction.
   Purpose: Provide security without stressing joints or chest.
   Mechanism: Deep-pressure input decreases stress responses via parasympathetic activation.
   Benefits: Less agitation, easier procedures (diapering, assessments), improved comfort.

4. Minimal handling protocol
   Description: Cluster necessary cares; avoid frequent repositioning.
   Purpose: Reduce fatigue and oxygen demand.
   Mechanism: Fewer disturbances lower sympathetic surges that increase respiratory effort.
   Benefits: Smoother vital signs, less desaturation, gentler end-of-life experience.

5. Non-nutritive sucking for comfort
   Description: Pacifier or gloved finger if oral anatomy allows.
   Purpose: Soothe and support natural reflexes.
   Mechanism: Rhythmic sucking organizes brainstem patterns and lowers stress.
   Benefits: Comfort, distraction during brief procedures.

6. Gentle chest support
   Description: Hands or cloth nest supporting the small thorax in semi-elevated position.
   Purpose: Ease work of breathing without forcing ventilation.
   Mechanism: Gravity-assisted diaphragmatic movement.
   Benefits: Slight comfort gain, less retraction discomfort.

7. Warmth optimization
   Description: Pre-warmed blankets, hats, and warmed delivery room.
   Purpose: Prevent hypothermia, which increases oxygen demand.
   Mechanism: Maintaining neutral thermal environment avoids metabolic stress.
   Benefits: Greater comfort and energy conservation.

8. Low-stimulation environment
   Description: Dim lights, soft voices, minimal alarms.
   Purpose: Reduce sensory overload.
   Mechanism: Lower catecholamines; calmer behavior.
   Benefits: Improved rest, less crying.

9. Aromatherapy (neutral, clinician-approved)
   Description: Very light, safe scents on caregiver cloth (never on baby).
   Purpose: Promote relaxation for family; not a treatment for the infant.
   Mechanism: Sensory association may ease parental stress.
   Benefits: Perceived calm during holding time.

10. Music or parental voice care
    Description: Soft lullabies or recorded parent voice.
    Purpose: Provide familiar soothing input.
    Mechanism: Auditory calming lowers stress responses.
    Benefits: Enhanced bonding, calmer infant.

11. Hand-hug and facilitated tucking during procedures
    Description: Hold limbs in flexion during diapering or brief assessments.
    Purpose: Prevent sudden joint stress.
    Mechanism: Proprioceptive input decreases startle.
    Benefits: Less distress and safer handling.

12. Oral moisture care
    Description: Swabs with sterile water or breast milk if safe.
    Purpose: Prevent dryness and discomfort.
    Mechanism: Moist mucosa reduces pain signals.
    Benefits: More comfortable infant, easier bonding kisses.

13. Pressure-injury prevention
    Description: Soft surfaces, frequent micro-reliefs without major repositioning.
    Purpose: Protect delicate skin and soft tissues.
    Mechanism: Reduce focal pressure and friction.
    Benefits: Skin integrity maintained during precious time.

14. Family-led touch routines
    Description: Teach parents safe, gentle touch patterns.
    Purpose: Empower families.
    Mechanism: Predictable touch cues anchor bonding and reduce infant stress.
    Benefits: Memory-making and reduced helplessness.

15. Scent cloth exchange
    Description: Parent keeps baby-scented cloth and vice versa.
    Purpose: Maintain connection when apart.
    Mechanism: Olfactory memory supports bonding hormones.
    Benefits: Comfort for family during grief.

B) Mind-body supports for parents

16. Guided breathing and grounding
    Purpose/Mechanism: Slow breathing reduces anxiety and sympathetic arousal; helps parents participate in decisions.
    Benefits: Clearer communication, calmer presence for baby.

17. Brief mindfulness check-ins
    Purpose/Mechanism: 5-minute mindfulness reduces acute distress; supports coping.
    Benefits: Better emotional regulation.

18. Meaning-making and legacy building
    Purpose/Mechanism: Create hand/footprints, photos, name ceremonies; supports grief processing.
    Benefits: Lasting memories and healthier bereavement.

19. Spiritual/chaplain support (if desired)
    Purpose/Mechanism: Align care with beliefs and values.
    Benefits: Reduced moral distress.

C) “Gene/education” counseling and planning (educational therapy)

20. Clear diagnosis education
    Purpose/Mechanism: Explain COL2A1 cause, lethality, and limits of treatment in plain words.
    Benefits: Informed, compassionate choices. NCBI

21. Birth plan and palliative pathway
    Purpose/Mechanism: Plan comfort-focused delivery, skin-to-skin, memory-making.
    Benefits: Care aligned with family goals.

22. Genetic counseling for future pregnancies
    Purpose/Mechanism: Discuss de novo risk, rare mosaicism, and options like CVS/amniocentesis or preimplantation testing if a variant is known.
    Benefits: Realistic recurrence counseling. NCBI

23. Siblings/extended-family education
    Purpose/Mechanism: Age-appropriate explanations reduce confusion and guilt.
    Benefits: Healthier family adjustment.

24. Social work and bereavement resources
    Purpose/Mechanism: Practical help (leave, transport, rituals) and grief support.
    Benefits: Reduced logistical and emotional burden.

25. Care team debrief and follow-up
    Purpose/Mechanism: Schedule post-loss check-ins for mental health screening and support.
    Benefits: Early identification of complicated grief or depression.

---

Medication-related supports

These medications do not treat or reverse Langer–Saldino achondrogenesis. In many cases, families choose comfort-only care without invasive interventions. Doses are individualized by clinicians. Items below describe typical purposes, not prescriptions.

1. Oxygen by nasal cannula (support, not a drug) with low-dose opioids (e.g., morphine)
   Class/Purpose: Analgesic; reduces air hunger.
   Timing: As needed for comfort.
   Mechanism: μ-opioid receptor activation reduces dyspnea perception.
   Side effects: Sedation; constipation; careful dosing required.

2. Oral sucrose (procedural comfort)
   Class: Non-opioid analgesic adjunct in neonates.
   Mechanism: Sweet-taste endorphin release.
   Side effects: Minimal with tiny doses.

3. Acetaminophen
   Class: Analgesic/antipyretic.
   Purpose: Mild pain/fever relief.
   Mechanism: Central COX modulation.
   Side effects: Liver risk at high doses.

4. Topical anesthetics (for brief procedures if pursued)
   Purpose: Reduce procedural pain.
   Side effects: Local irritation; methemoglobinemia is rare with proper use.

5. Low-dose benzodiazepine (e.g., midazolam)
   Purpose: Anxiety/agitation relief if needed.
   Mechanism: GABA-A enhancement.
   Side effects: Respiratory depression—use only in monitored settings.

6. Anticholinergic drops for secretions (e.g., glycopyrrolate)
   Purpose: Reduce terminal secretions (“rattle”).
   Side effects: Dry mouth, tachycardia.

7. Antiemetics (ondansetron)
   Purpose: Nausea control if present.
   Mechanism: 5-HT3 blockade.
   Side effects: QT effects (rare).

8. Antireflux agents (H2 blocker)
   Purpose: Reflux discomfort if feeding for comfort.
   Side effects: Altered gastric flora.

9. Vitamin K (routine newborn prophylaxis)
   Purpose: Prevent bleeding; standard of care.
   Side effects: Very rare with single dose.

10. Lubricating eye drops
    Purpose: Prevent corneal dryness if eyelids do not close fully.
    Side effects: Minimal.

11. Topical barrier creams
    Purpose: Protect skin.
    Side effects: Minimal.

12. Oral comfort feeds (few drops of breast milk)
    Purpose: Taste and bonding if safe; not a “drug,” but a deliberate comfort intervention.
    Side effects: Aspiration risk—team guidance required.

13. Antiseizure medicines (rarely needed)
    Purpose: Treat seizures if they occur.
    Side effects: Drug-specific.

14. Antibiotics (only if clear infection and family chooses active treatment)
    Purpose: Treat proven infection; does not change underlying condition.
    Side effects: Drug-specific.

15. Antenatal corticosteroids for lung maturity (during pregnancy, if timing fits and team advises)
    Purpose: General preterm lung support; not effective against lung hypoplasia seen in ACG2 but may be given per obstetric protocols.
    Side effects: Maternal/fetal glucose effects. (Evidence for benefit in ACG2 is absent.)

---

Dietary “molecular” supplements

There are no supplements that alter ACG2. The only nutrition advice is for the pregnant parent’s health and general fetal well-being. Any supplement should be approved by the obstetric team.

1. Folic acid (400–800 µg/day)
   Function: Neural tube protection; standard prenatal care.
   Mechanism: One-carbon metabolism support.

2. Prenatal multivitamin
   Function: Broad micronutrient sufficiency.
   Mechanism: Prevents deficiencies that can affect general pregnancy health.

3. Iron (as needed for anemia)
   Function: Maternal hemoglobin support.
   Mechanism: Replaces iron stores.

4. Iodine (150 µg/day total in prenatal)
   Function: Thyroid hormone synthesis.
   Mechanism: Supports neurodevelopment.

5. Vitamin D (per labs/guidelines)
   Function: Bone/mineral metabolism for mother.
   Mechanism: Calcium–phosphate homeostasis.

6. Calcium (diet first; supplement if needed)
   Function: Maternal bone health.
   Mechanism: Adequate calcium intake.

7. Omega-3 DHA
   Function: Supports general fetal neural development.
   Mechanism: Membrane PUFA incorporation.

8. Choline
   Function: Neurodevelopmental support.
   Mechanism: Methyl donor; cell membrane precursor.

9. Probiotics (if tolerated)
   Function: Maternal GI comfort.
   Mechanism: Microbiome effects.

10. Avoid “bone growth” or “collagen boosting” supplements for the fetus
    Function: None for ACG2.
    Mechanism: No evidence; may cause harm or false hope.

---

Regenerative/stem-cell” drugs

• There are no immunity boosters, regenerative drugs, or stem-cell therapies proven to help ACG2. The problem is a global, structural collagen defect during embryonic development; it cannot be reversed after the skeleton forms. Experimental ideas in lab settings do not apply to real patients today. Families should be protected from unproven, costly, or exploitative offers. Future advances in gene editing are a research topic but are not available in clinical care for this condition. NCBI

---

5 procedures/surgeries (why they are or aren’t done)

1. Comfort-focused delivery and immediate skin-to-skin
   Why done: To prioritize bonding and reduce distress.

2. Non-invasive ventilation or brief intubation (only if specifically chosen)
   Why done: In rare cases, families may request short support to allow time for meeting the baby. It does not change outcome.

3. Feeding tube placement
   Why done: Usually not pursued; risks outweigh benefits given the prognosis.

4. Tracheostomy or long-term ventilation
   Why done: Not recommended; cannot overcome lung hypoplasia.

5. Autopsy (with consent)
   Why done: Clarifies diagnosis; supports genetic counseling for the future.

---

10 prevention points (focused on counseling and planning)

1. Early detailed ultrasound in future pregnancies if prior history. PMC

2. Targeted COL2A1 testing in future pregnancy if a family variant was found. NCBI

3. Preimplantation genetic testing (PGT) if variant known and IVF is chosen.

4. Offer chorionic villus sampling at 11–13 weeks for early molecular diagnosis.

5. Offer amniocentesis around 15–18 weeks if preferred.

6. Discuss rare parental mosaicism and small recurrence risk despite de novo nature. NCBI

7. Document and share prior reports (imaging, genetics) with obstetric teams.

8. Optimize maternal health (supplements per prenatal standards; avoid teratogens—though these do not cause ACG2).

9. Plan care location with high-level fetal imaging and genetics available.

10. Respect cultural/ethical preferences in decision-making, including options within local laws.

---

When to see a doctor

• During pregnancy: see your clinician as soon as an ultrasound suggests very short limbs, a small chest, or poor bone mineralization. Ask for maternal–fetal medicine and clinical genetics input, and discuss molecular testing options (CVS or amnio). PMC

• After birth: if ACG2 is suspected, immediate care should focus on comfort and family wishes. Ask to meet palliative care and bereavement support early.

• Between pregnancies: schedule preconception genetic counseling to review the prior results and discuss options in the next pregnancy. NCBI

---

What to eat and what to avoid

These suggestions are general prenatal health tips. They do not change ACG2 risk in the current pregnancy unless a known COL2A1 variant is being specifically tested for.

1. Eat a balanced prenatal diet rich in fruits, vegetables, whole grains, legumes, lean proteins, and healthy fats.

2. Include prenatal vitamins with folic acid and iodine; add iron, vitamin D, or calcium only if advised.

3. Hydrate well; regular light activity if your clinician says it is safe.

4. Avoid alcohol, smoking, vaping, and recreational drugs.

5. Limit high-mercury fish (e.g., shark, swordfish); choose low-mercury options.

6. Avoid unpasteurized dairy and undercooked meats for infection safety.

7. Avoid megadose supplements or “collagen boosters” marketed for the fetus.

8. Discuss any herbal products with your clinician first.

9. Manage nausea and reflux with safe dietary strategies per obstetric advice.

10. Follow your clinician’s individualized nutrition plan.

---

Frequently asked questions

1. Is Langer–Saldino achondrogenesis always fatal?
   Sadly, yes. The small chest and underdeveloped lungs make survival beyond birth extremely unlikely. Care focuses on comfort and family support. MedlinePlus

2. Did we do something to cause it?
   No. It almost always results from a new genetic change that no one could predict or prevent. NCBI

3. Can ventilators or surgery fix the small lungs?
   No. Ventilation cannot create lung tissue that did not develop. It may be used briefly only for time with family.

4. Are there medicines or supplements that help?
   No disease-modifying therapies exist. Medicines are used only to reduce discomfort or anxiety.

5. Is this the same as achondroplasia?
   No. Achondroplasia is a different, non-lethal bone condition (FGFR3 gene). Achondrogenesis (type II) is much more severe and usually lethal.

6. Can we know for sure before birth?
   A combination of ultrasound patterns, fetal imaging, and molecular testing of COL2A1 can confirm the diagnosis during pregnancy. PMC

7. If it’s autosomal dominant, will it happen again?
   Most cases are de novo, so recurrence risk is low. Rarely, one parent may have germline mosaicism, giving a small recurrence risk; genetic counseling explains options. NCBI

8. What about eye or hearing issues in type II collagen disorders?
   Other COL2A1 disorders can affect eyes/ears and joints, but ACG2 is so severe that these longer-term features are not the main issue. NCBI

9. Can stem cells or gene therapy help now?
   No. These are research ideas and not available or effective for ACG2 at this time. NCBI

10. What decisions do families face?
    Families consider comfort-focused birth plans, memory-making, and whether to try brief support for bonding. Palliative care can guide these choices.

11. What is Pierre Robin sequence and why mentioned?
    It is a set of facial findings (small lower jaw, tongue falling back, possible cleft palate) sometimes seen with COL2A1 disorders, including ACG2. NCBI

12. How is ACG2 different from type I forms?
    Different genes and imaging patterns; type II usually has better skull ossification but similar lethal severity. SpringerOpen

13. Should we do an autopsy?
    It’s a personal choice. It can confirm the diagnosis and help future pregnancy planning.

14. What support exists after loss?
    Hospitals offer bereavement programs, social work, chaplaincy, and mental-health referrals. Ask your team to connect you.

15. What should we plan for a future pregnancy?
    Arrange preconception genetics, early ultrasounds, and consider CVS/amnio or PGT if a family variant is known. NCB

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 04, 2025.